{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:15:43Z","timestamp":1769638543008,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Densitometry"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jocd.2013.09.018","type":"journal-article","created":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T17:46:09Z","timestamp":1382723169000},"page":"490-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Understanding and Communicating the Benefits and Risks of\u00a0Denosumab, Raloxifene, and Teriparatide for the Treatment of\u00a0Osteoporosis"],"prefix":"10.1016","volume":"17","author":[{"given":"E. Michael","family":"Lewiecki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve T.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas C.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Shawn","family":"Davison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Dian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chui K.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Kendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocd.2013.09.018_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","article-title":"Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis","volume":"148","author":"MacLean","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2013.09.018_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2105\/AJPH.92.2.271","article-title":"Recognition of osteoporosis by primary care physicians","volume":"92","author":"Gehlbach","year":"2002","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jocd.2013.09.018_bib3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0002-9343(03)00357-7","article-title":"Underuse of osteoporosis medications in elderly patients with fractures","volume":"115","author":"Solomon","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.jocd.2013.09.018_bib4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2013.09.018_bib5","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.amjmed.2005.12.018","article-title":"Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem","volume":"119","author":"Cramer","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jocd.2013.09.018_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am\u00a0J Med"},{"key":"10.1016\/j.jocd.2013.09.018_bib7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2013.09.018_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s001980070097","article-title":"Study subjects and ordinary patients","volume":"11","author":"Dowd","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2013.09.018_bib9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/0272989X9901900411","article-title":"How should effectiveness of risk communication to aid patients' decisions be judged? A review of the literature","volume":"19","author":"Edwards","year":"1999","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jocd.2013.09.018_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jocd.2010.06.005","article-title":"Risk communication and shared decision making in the care of patients with osteoporosis","volume":"13","author":"Lewiecki","year":"2010","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2013.09.018_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11914-011-0056-1","article-title":"The role of risk communication in the care of osteoporosis","volume":"9","author":"Lewiecki","year":"2011","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.jocd.2013.09.018_bib12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0277-9536(02)00056-4","article-title":"What are the ingredients for a successful evidence-based patient choice consultation?: A qualitative study","volume":"56","author":"Ford","year":"2003","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.jocd.2013.09.018_bib13","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2013.09.018_bib14","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for\u00a0the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2013.09.018_bib15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2013.09.018_bib16","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2013.09.018_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2013.09.018_bib18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2165\/11207370-000000000-00000","article-title":"Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours","volume":"71","author":"Scott","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jocd.2013.09.018_bib19","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2013.09.018_bib20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2013.09.018_bib21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","article-title":"Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women","volume":"30","author":"Neele","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2013.09.018_bib22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jama.287.7.847","article-title":"Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial","volume":"287","author":"Barrett-Connor","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2013.09.018_bib23","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jocd.2013.09.018_bib24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2147\/CIA.S3344","article-title":"Managing the risk of invasive breast cancer in\u00a0women at risk for breast cancer and osteoporosis: the role of raloxifene","volume":"3","author":"Vogel","year":"2008","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jocd.2013.09.018_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2013.09.018_bib26","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00198-010-1276-4","article-title":"Stroke in relation to use of raloxifene and other drugs against osteoporosis","volume":"22","author":"Vestergaard","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2013.09.018_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jocd.2013.09.018_bib28","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2013.09.018_bib29","first-page":"558","article-title":"Adverse events reported by postmenopausal women in controlled trials with raloxifene","volume":"93","author":"Davies","year":"1999","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jocd.2013.09.018_bib30","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2013.09.018_bib31","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2013.09.018_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","article-title":"Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in\u00a0postmenopausal women with osteoporosis","volume":"19","author":"Adami","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2013.09.018_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2013.09.018_bib34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in\u00a0F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.jocd.2013.09.018_bib35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.061111","article-title":"Osteosarcoma and teriparatide?","volume":"22","author":"Harper","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2013.09.018_bib36","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00198-009-1004-0","article-title":"Of mice and\u00a0men: divergent risks of teriparatide-induced osteosarcoma","volume":"21","author":"Subbiah","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2013.09.018_bib37","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","article-title":"The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years","volume":"27","author":"Andrews","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2013.09.018_bib38","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1210\/jc.2006-2439","article-title":"Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide","volume":"92","author":"Miller","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2013.09.018_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocd.2010.12.001","article-title":"Osteoporosis update from the 2010 santa fe bone symposium","volume":"14","author":"Lewiecki","year":"2011","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.jocd.2013.09.018_bib40","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2013.09.018_bib41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"}],"container-title":["Journal of Clinical Densitometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695013001807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695013001807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:39:40Z","timestamp":1761082780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094695013001807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1094695013001807"],"URL":"https:\/\/doi.org\/10.1016\/j.jocd.2013.09.018","relation":{},"ISSN":["1094-6950"],"issn-type":[{"value":"1094-6950","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding and Communicating the Benefits and Risks of\u00a0Denosumab, Raloxifene, and Teriparatide for the Treatment of\u00a0Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Densitometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocd.2013.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}